SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS Russian patent published in 2021 - IPC C07K16/10 C12N15/13 A61K39/40 A61P31/12 

FIELD: biotechnology; immunology; virology.

SUBSTANCE: described is a single-domain antibody that specifically binds to RBDS of the SARS-CoV-2 virus protein, has a virus neutralizing activity and has the amino acid sequence SEQ ID NO:1, or SEQ ID NO:2, or SEQ ID NO:3. Also proposed is an oligomerized single-domain antibody that specifically binds to the RBDS protein of the SARS-CoV-2 virus, having a virus neutralizing activity, containing any variant of the created single-domain antibody as a monomeric block. In addition, an antibody has been created, which is a single-domain antibody fused to the Fc fragment of human immunoglobulin G1, which specifically binds to RBDS of the SARS-CoV-2 virus protein and has a virus neutralizing activity having the final amino acid sequence of SEQ ID NO:7, or SEQ ID NO:8, or SEQ ID NO:9. An oligomerized antibody has also been created, which is an oligomerized single-domain antibody fused to the Fc fragment of human immunoglobulin G1, which specifically binds to RBDS of the SARS-CoV-2 virus protein and has a virus neutralizing activity. A method for therapy or emergency prevention of diseases caused by the SARS-CoV-2 virus has been developed, which consists in introducing into the mammalian body in an effective amount of any created antibody.

EFFECT: arsenal of means for therapy and emergency prevention of diseases caused by the SARS-CoV-2 virus is expanded.

5 cl, 8 dwg, 5 tbl, 15 ex